SHA: 600196

Explore the latest insights on SHA: 600196 and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of SHA: 600196’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Merck's Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC
CompanyDrug

Merck’s Subcutaneous Pembrolizumab KEYJECT Wins MHLW Approval Across All KEYTRUDA Indications in Japan – Phase III Shows Comparable Exposure and 45% ORR in First-Line Metastatic NSCLC

Merck & Co., Inc. (MSD; NYSE: MRK) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa‑pmph), a subcutaneous formulation of its…

Roche's Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Roche’s Susvimo Wins European Commission Approval for nAMD – Refillable Ranibizumab Implant Delivers Vision Outcomes Equivalent to Monthly Injections with Just Two Refills Per Year

Grünenthal to Acquire Bayer's Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Grünenthal to Acquire Bayer’s Stivarga (Regorafenib) for Up to €375 Million – Oral Multikinase Oncology Franchise Changes Hands Ahead of 2029–2030 Loss of Exclusivity

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Fosun Pharmaceutical Secures NMPA Approval for Phase II Study of FCN-338 and FCN-647 in Chronic Lymphocytic Leukemia

CompanyDrug

Fosun Pharmaceutical’s HanDaYuan Seeks NMPA Approval for Expanded Indications in Autoimmune Treatments

CompanyDeals

Shanghai Fosun Pharmaceutical Partners with Nanning City to Broaden Collaboration in Biopharma and Beyond

CompanyDrug

Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis

CompanyDrug

Shanghai Henlius Secures Indonesian Approval for HanSiZhuang in Small-Cell Lung Cancer

CompanyDrug

Fosun’s HLX42 Receives Fast-Track Designation from FDA for NSCLC Treatment

CompanyDrug

Shanghai Fosun to Exclusively Commercialize Generic Entresto in China

CompanyDeals

Fosun Pharmaceutical Secures GHIT Fund Investment for Malaria Drug Trial

Show More